Nmp4/CIZ Closes the Parathyroid Hormone Anabolic Window

Chronic degenerative diseases are increasing with the aging U.S. population. One consequence of this phenomenon is the need for long-term osteoporosis therapies. Parathyroid hormone (PTH), the only FDA-approved treatment that adds bone to the aged skeleton, loses its potency within two years of init...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Bidwell, Joseph P., Childress, Paul, Alvarez, Marta B., Hood, Mark, He, Yongzheng, Pavalko, Fredrick M., Kacena, Melissa A., Yang, Feng-Chun
Format: Artigo
Idioma:Inglês
Publicat: 2012
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3586259/
https://ncbi.nlm.nih.gov/pubmed/23140162
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars